EXHIBIT 99.2

GENENTECH, INC. CONSOLIDATED STATEMENTS OF INCOME DATA (in thousands, except per share amounts) (unaudited)
	Three Months Ended September 30,
		2005		2004
Revenues:
Product sales	$	1,450,979	$	1,005,511
Royalties		237,777		153,942
Contract revenue		63,066		43,191
Total operating revenues		1,751,822		1,202,644
Costs and expenses:
Cost of sales		230,127		165,990
Research and development		328,850		234,086
Marketing, general and administrative		349,323		264,648
Collaboration profit sharing		219,591		151,894
Recurring charges related to redemption		27,191		34,534
Special items:  litigation-related		13,507		13,419
Total costs and expenses		1,168,589		864,571
Operating margin		583,233		338,073
Other income, net(1)		22,391		23,510
Income before taxes		605,624		361,583
Income tax provision		246,211		130,709
Net income	$	359,413	$	230,874
Earnings per share:
Basic	$	0.34	$	0.22
Diluted	$	0.33	$	0.21
Weighted average shares used to compute earnings per share:
Basic		1,060,539		1,055,140
Diluted		1,086,964		1,077,093

___________________

(1) "Other income, net" includes interest income, interest expense, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com.

- 1 -

GENENTECH, INC. CONSOLIDATED STATEMENTS OF INCOME DATA (in thousands, except per share amounts) (unaudited)
	Nine Months Ended September 30,
		2005		2004
Revenues:
Product sales	$	3,911,095	$	2,682,577
Royalties		670,014		459,899
Contract revenue		159,170		163,381
Total operating revenues		4,740,279		3,305,857
Costs and expenses:
Cost of sales		750,649		467,153
Research and development		850,215		637,317
Marketing, general and administrative		1,021,174		788,616
Collaboration profit sharing		594,666		423,546
Recurring charges related to redemption		96,155		110,952
Special items:  litigation-related		44,291		40,276
Total costs and expenses		3,357,150		2,467,860
Operating margin		1,383,129		837,997
Other income, net(1)		70,290		61,274
Income before taxes		1,453,419		899,271
Income tax provision		513,666		321,040
Net income	$	939,753	$	578,231
Earnings per share:
Basic	$	0.89	$	0.55
Diluted	$	0.87	$	0.53
Weighted average shares used to compute earnings per share:
Basic		1,055,028		1,057,006
Diluted		1,080,921		1,082,081

___________________

(1) "Other income, net" includes interest income, interest expense, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com.

- 2 -

GENENTECH, INC. CONSOLIDATED BALANCE SHEETS DATA (in thousands) (unaudited)
	September 30,
	2005		2004
Selected balance sheet data:
Cash, cash equivalents and short-term investments	$	2,905,543	$	1,760,164
Accounts receivable - product sales, net		509,465		548,555
Accounts receivable - royalties, net		264,179		193,650
Accounts receivable - other, net		189,341		143,622
Inventories		621,389		559,920
Long-term marketable debt and equity securities		1,242,866		1,310,422
Property, plant and equipment, net		3,128,089		1,922,313
Goodwill		1,315,019		1,315,019
Other intangible assets		587,911		677,049
Long-term assets		1,030,842		774,435
Total assets		12,099,306		9,408,360
Total current liabilities		1,354,938		1,106,656
Total liabilities		4,376,048		2,441,064
Total stockholders' equity		7,723,258		6,967,566
Year-to-date:
Capital expenditures	$	1,106,930	$	418,214
Total depreciation and amortization expense		275,632		259,583

- 3 -

GENENTECH, INC. NET PRODUCT SALES DETAIL (in thousands) (unaudited)
	Three Months Ended September 30,
	2005		2004
Net U.S. Product Sales
Rituxan	$	456,227	$	393,000
Herceptin		215,148		126,300
Avastin		325,156		183,003
Growth Hormone		88,585		84,931
Thrombolytics		57,903		52,867
Pulmozyme		46,593		39,816
Xolair		81,550		53,856
Raptiva		20,887		16,265
Tarceva		73,222		-
Total U.S. product sales		1,365,271		950,038
Net product sales to collaborators		85,708		55,473
Total Product Sales	$	1,450,979	$	1,005,511
	Nine Months Ended September 30,
	2005		2004
Net U.S. Product Sales
Rituxan	$	1,347,125	$	1,144,813
Herceptin		497,205		352,996
Avastin		773,695		354,134
Growth Hormone		275,570		256,896
Thrombolytics		160,105		147,133
Pulmozyme		137,482		114,340
Xolair		227,183		127,332
Raptiva		58,803		35,971
Tarceva		190,993		-
Total U.S. product sales		3,668,161		2,533,615
Net product sales to collaborators		242,934		148,962
Total Product Sales	$	3,911,095	$	2,682,577

- 4 -